» Articles » PMID: 28267594

Effects of Colistin on Biofilm Matrices of Escherichia Coli and Staphylococcus Aureus

Overview
Date 2017 Mar 8
PMID 28267594
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Biofilms are the preferred environment of micro-organisms on various surfaces such as catheters and heart valves, are associated with numerous difficult-to-treat and recurrent infections, and confer an extreme increase in antibiotic tolerance to most compounds. The aim of this study was to evaluate how colistin affects both the extracellular biofilm matrix and the embedded bacteria in biofilms of methicillin-resistant Staphylococcus aureus (MRSA), a species with intrinsic resistance to colistin, and colistin-susceptible Escherichia coli. Biofilms of MRSA and E. coli were treated with different concentrations of colistin. The minimum biofilm eradication concentration (MBEC) and the effectiveness of colistin at reducing the planktonic fraction were defined as the remaining viable bacteria measured as CFU/mL. In addition, biofilm-embedded cells were LIVE/DEAD-stained and were analysed by confocal laser scanning microscopy (CLSM). Quantification of the biofilm CLSM images was conducted using an open-access in-house algorithm (qBA). In contrast to MRSA, E. coli biofilms and planktonic cells were significantly reduced by colistin in a concentration-dependent manner. Nevertheless, colistin has been shown to exert a matrix-reducing effect following treatment both in laboratory strains and clinical isolates of MRSA and E. coli. Because exposure to colistin rapidly triggered the emergence of highly resistant clones, monotherapy with colistin should be applied with caution. These results suggest that colistin destabilises the biofilm matrix structure even in species with intrinsic colistin resistance, such as S. aureus, leading to the release of planktonic cells that are more susceptible to antibiotics.

Citing Articles

Antibiotic-Polyphosphate Nanocomplexes: A Promising System for Effective Biofilm Eradication.

To D, Blanco Massani M, Coraca-Huber D, Seybold A, Ricci F, Zoller K Int J Nanomedicine. 2024; 19:9707-9725.

PMID: 39309185 PMC: 11416784. DOI: 10.2147/IJN.S473241.


Antibiotics with antibiofilm activity - rifampicin and beyond.

Ferreira L, Pos E, Nogueira D, Ferreira F, Sousa R, Abreu M Front Microbiol. 2024; 15:1435720.

PMID: 39268543 PMC: 11391936. DOI: 10.3389/fmicb.2024.1435720.


Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies.

Dsouza F, Dinesh S, Sharma S Arch Microbiol. 2024; 206(2):85.

PMID: 38300317 DOI: 10.1007/s00203-023-03802-7.


Polymyxin B and ethylenediaminetetraacetic acid act synergistically against and .

Hale S, Cameron A, Lux C, Biswas K, Kim R, OCarroll M Microbiol Spectr. 2024; 12(2):e0170923.

PMID: 38168683 PMC: 10845947. DOI: 10.1128/spectrum.01709-23.


In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia.

Bayatinejad G, Salehi M, Beigverdi R, Halimi S, Emaneini M, Jabalameli F BMC Microbiol. 2023; 23(1):298.

PMID: 37864176 PMC: 10588070. DOI: 10.1186/s12866-023-03039-w.